Nav: Home

Synodos for NF2 Consortium publishes key results of its work

June 14, 2018

The Synodos for NF2 consortium of the Children's Tumor Foundation (CTF) today published its first set of results and released its second set of data in the leading scientific journal PLOS ONE. Synodos is the Foundation's innovative team science collaborative that brings researchers, clinicians and patients together in a shared data environment, in order to develop treatments for NF patients at an accelerated pace. Established in 2014, the $3 million project is a combined effort among 12 leading research labs at 8 institutions.

The Synodos for NF2 team released its first set of results and data in the scientific journal PLOS ONE, entitled Traditional and Systems Biology Based Drug Discovery for the Rare Tumor Syndrome Neurofibromatosis Type 2. In line with the Foundation's principles of open-access and data sharing, the journal is making the full article available to all, with immediate access to the data.

The primary aim of the Synodos for NF2 team was to find treatments that could be used for both meningioma and schwannoma by using a drug discovery approach of selecting mechanistically relevant compounds. The team integrated innovative research approaches such as Next Generation Sequencing (NGS) and Kinome profiling. These two techniques allow analysis of the alteration in expression of genes and proteins in cells or animal models.

A core finding was that while schwannomas and meningiomas are both initiated by merlin loss, the distinctly different responses to that loss of function are likely to prescribe that a single drug (target) is unlikely to be optimally effective in both cell types. Instead, it is likely that different drugs or combos (a cocktail of two or more drugs) aimed at distinct targets will be required to treat these two tumor types. In fact, the first three single drugs tested (Panobinostat, CUDC-907 and GSK2126458) were only mildly active in preventing tumors from growing. The next set of experiments started looking at drug combinations and the team reported that the drug Dasatininb, a multi-kinase inhibitor in combination with AZD-2014 or INK128, both dual mTORC1/2 inhibitors, suppressed tumor growth up to ~85% in a meningioma animal model (this last result was reported earlier in March 2018 by the Synodos team in the scientific journal Neuro-Oncology. That publication can be found here:

Additionally, the work of the Synodos for NF2 consortium has filled a critical gap in the understanding of how the NF2 mutation and the absence of merlin influence tumor cell behavior in both meningiomas and schwannomas. The collective effort of twelve research groups succeeded in:
    (1) creating a new pipeline of well-validated tools for NF2-associated drug discovery with fully characterized isogenic pairs of meningioma and schwannoma cell systems;

    (2) gaining conceptual insights into disease mechanisms via transcriptome and kinome interrogation that indicate that different drugs are likely to be needed to treat meningioma and schwannoma;

    (3) validating pathways and targets that are altered based on tumor type and in response to targeted pathway inhibition in the setting of NF2; and

    (4) building an openly accessible database for community sharing and mining of drug treatment, transcriptome and kinome data from isogenic schwannoma and meningioma cell systems. This data presents several targets to consider for single agent and combination therapy in the short term, and provides a deep and rich open access data resource for the broader research community seeking treatments for NF2-associated meningioma and schwannoma for the long term.

The Synodos team is actively working on finalizing the latest findings, which will also be published as a follow up to this research release.

Ultimately, these newly released results and data are providing, for the first time, a critical resource that will be invaluable to the NF2 research community. This work illustrates that the CTF model of bringing together scientists of diverse expertise areas improves the ability to discover new therapeutic strategies to treat these highly devastating tumors.

The full article in PLOS ONE can be found here:

The Children's Tumor Foundation is a 501(c)(3) not-for-profit organization dedicated to funding and driving innovative research that will result in effective treatments for the millions of people worldwide living with neurofibromatosis (NF), a term for three distinct disorders: NF1, NF2, and schwannomatosis. NF causes tumors to grow on nerves throughout the body and may lead to blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain, and cancer. NF affects 1 in every 3,000 births across all populations equally. There is no cure yet - but the Children's Tumor Foundation mission of driving research, expanding knowledge, and advancing care for the NF community fosters our vision of one day ending NF. For more information, please visit


Simon Vukelj
Vice President, Marketing and Communications
Children's Tumor Foundation
(212) 344-7568

Children's Tumor Foundation

Related Drug Discovery Articles:

Fat-fighting drug discovery
Cancer-fighting compound fights obesity and diabetes.
New cell models for ocular drug discovery
Researchers at the University of Eastern Finland have developed two new cell models that can open up new avenues for ocular drug discovery.
Machine learning's next frontier: Epigenetic drug discovery
Scientists at Sanford Burnham Prebys Medical Discovery Institute have developed a machine-learning algorithm that gleans information from microscope images -- allowing for high-throughput epigenetic drug screens that could unlock new treatments for cancer, heart disease, mental illness and more.
Discovery of how colorectal cancer drug works will help more patients
Some colorectal cancer patients with a certain gene mutation benefit from a chemotherapy drug called cetuximab, although the mechanism of how this drug worked was unknown.
Speeding up the drug discovery process to help patients
An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.
Learning from nature's bounty: New libraries for drug discovery
Natural products make some of our most potent medicines, among which macrocycles with their large carbon-rich ring systems are one class.
Bioluminescence sensors make new approaches to drug discovery possible
Canadian and Brazilian researchers describe the use of 13 molecular tools for measuring different intracellular signaling pathways and evaluating the action mechanisms of new drugs.
Light-based production of drug-discovery molecules
EPFL chemists have developed a light-based chemical method for cheap and simple production of chemical molecules used in drug discovery, such as muscle relaxants and antimicrobials.
New drug discovery could halt spread of brain cancer
A team of researchers at Virginia Tech may have found a solution to stopping the spread of glioblastoma with a new drug and cancer treatment method.
Arming drug hunters, chemists design new reaction for drug discovery
Colorado State University organic chemists have forged a powerful new tool for drug hunters -- a simple, elegantly designed chemical reaction that could fling open an underexplored wing of biologically relevant chemistry.
More Drug Discovery News and Drug Discovery Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#555 Coronavirus
It's everywhere, and it felt disingenuous for us here at Science for the People to avoid it, so here is our episode on Coronavirus. It's ok to give this one a skip if this isn't what you want to listen to right now. Check out the links below for other great podcasts mentioned in the intro. Host Rachelle Saunders gets us up to date on what the Coronavirus is, how it spreads, and what we know and don't know with Dr Jason Kindrachuk, Assistant Professor in the Department of Medical Microbiology and infectious diseases at the University of Manitoba. And...
Now Playing: Radiolab

Dispatch 1: Numbers
In a recent Radiolab group huddle, with coronavirus unraveling around us, the team found themselves grappling with all the numbers connected to COVID-19. Our new found 6 foot bubbles of personal space. Three percent mortality rate (or 1, or 2, or 4). 7,000 cases (now, much much more). So in the wake of that meeting, we reflect on the onslaught of numbers - what they reveal, and what they hide.  Support Radiolab today at